Key result
Chemotherapy in patients with acute lymphoblastic leukemia led to a significant drop in left ventricular ejection fraction (p<0.001) and subclinical vascular remodeling after 3 months.
Why the study?
Chemotherapy-induced cardiotoxicity may occur during treatment or cause severe cardiac failure years later, prompting the evaluation of LV and vascular remodeling parameters for early diagnosis in ALL.
Do echocardiographic and vascular remodeling parameters detect early subclinical cardiotoxicity in patients with acute lymphoblastic leukemia undergoing chemotherapy?
Cohort (n=35)
Do echocardiographic and vascular remodeling parameters detect early subclinical cardiotoxicity in patients with acute lymphoblastic leukemia undergoing chemotherapy?
p-value: p=<0.001
Echocardiographic and vascular parameters such as GLS, IMT, and PWVAo can detect subclinical cardiotoxicity as early as 3 months after starting chemotherapy in ALL patients.
May support early subclinical monitoring in ALL chemotherapy patients; leaves open need for outcome-linked validation before practice change.
No takes yet. Share an insight, caveat, or question.
Militaru et al. (2019) conducted a cohort in Acute lymphoblastic leukemia (ALL) (n=35). Chemotherapy vs. Baseline (before chemotherapy) was evaluated on Left ventricular ejection fraction (LVEF) and vascular remodeling parameters (p=<0.001). Chemotherapy in patients with acute lymphoblastic leukemia led to a significant drop in left ventricular ejection fraction (p<0.001) and subclinical vascular remodeling after 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: